子宫内膜异位症：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 德国子宫内膜异位症市场预计将从 2025 年的 1.24 亿美元增长到 2035 年的 4.14 亿美元，这反映了受新型荷尔蒙疗法普及推动的强劲两位数增长。
• 市场扩张受以下因素支撑：
• 扩大口服 GnRH 拮抗剂和先进荷尔蒙疗法的应用。
• 诊断和治疗率的提高
• 儘管患者数量增长缓慢，但由于治疗週期长且存在高价治疗方法，市场规模正在扩大。
• 未来的成长取决于能够持续缓解症状并降低復发率的疾病修正治疗的研发。

子宫内膜异位症概述

子宫内膜异位症是一种雌激素依赖性的慢性全身性发炎疾病，其特征是子宫内膜样组织出现在卵巢腔以外的部位。这些异位病灶最常位于骨盆腔腹膜、卵巢和子宫荐骨韧带，并分为三种主要表型：浅层腹膜子宫内膜异位症、卵巢子宫内膜异位症和深部浸润性子宫内膜异位症（DIE），后者可扩散至肠道和膀胱等器官。此疾病的进展与异位组织的周期性雌激素依赖性活动有关，导致反覆出血、慢性发炎、纤维化和粘连形成。临床上，它表现为严重的慢性骨盆疼痛、月经、性交疼痛和不孕，严重影响患者的生活品质。特别是，由于疾病的严重程度与 ASRM 分类等分期系统没有一致的相关性，因此越来越倾向于基于症状、影像学支持的诊断。

目前尚无根治性治疗方法，治疗重点在于长期控制症状。治疗方法包括手术切除病灶和抑制雌激素生成的荷尔蒙疗法，例如黄体素和促性腺激素释放激素拮抗剂（如依拉戈利克斯、瑞卢戈利克斯）。儘管有多种治疗选择，但復发和症状控制不佳的情况仍然很常见，表明仍有未被满足的医疗需求。

主要亮点

• 在美国，由于人们意识的提高和诊断技术的改进，有症状病例的数量预计将从 2025 年的 441 万例增加到 2035 年的 472 万例，呈现稳定增长（年复合增长率为 0.7%）。
• 这种疾病的诊断往往存在严重延误，且症状多种多样，因此难以进行有效的疾病管理。
• 缺乏根治性治疗方法和高復发率凸显了对更持久、更有针对性的治疗方案的迫切需求。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Kissei Pharmaceutical Co., Ltd.
• Hope Medicine（Nanjing）Co., Ltd.
• Organon and Co
• Gesynta Pharma AB
• Nanjing Chia-tai Tianqing Pharmaceutical
• AbbVie
• Sumitomo Pharma Switzerland GmbH
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Jiangsu HengRui Medicine Co., Ltd.

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
• 重点
• 诊断和治疗过程/演算法
• 主要治疗方法概述及KOL洞察
• 新兴治疗方法
• 重点
• 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
• 值得关注的早期研发管线

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Endometriosis Market Outlook

Thelansis's "Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Endometriosis Overview

Endometriosis is a chronic, estrogen-dependent, systemic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. These ectopic lesions most commonly localize to the pelvic peritoneum, ovaries, and uterosacral ligaments, and are classified into three major phenotypes: superficial peritoneal endometriosis, ovarian endometriomas, and deep infiltrating endometriosis (DIE), which can involve organs such as the bowel and bladder. The disease is driven by cyclic, estrogen-mediated activity of ectopic tissue, leading to recurrent bleeding, chronic inflammation, fibrosis, and adhesion formation. Clinically, this manifests as severe chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility, significantly impairing quality of life. Notably, disease severity does not consistently correlate with staging systems such as the ASRM classification, prompting a shift toward symptom-driven and imaging-supported diagnosis.

There is currently no definitive cure, and management is centered on long-term symptom control. Treatment approaches include surgical intervention for lesion excision and hormonal therapies aimed at suppressing estrogen production, such as progestins and GnRH antagonists (e.g., elagolix, relugolix). Despite available options, recurrence and suboptimal symptom control remain common, underscoring persistent unmet need.

Key Highlights

• In the US, symptomatic cases are projected to increase from 4.41M in 2025 to 4.72M by 2035, reflecting steady growth (0.7% CAGR) driven by improved awareness and diagnosis.
• The disease is associated with substantial diagnostic delays and heterogeneous presentation, complicating effective disease management.
• Lack of curative therapies and high recurrence rates highlight a significant unmet need for more durable and targeted treatment options.

Market Overview

• The Germany endometriosis market is projected to grow from $124M in 2025 to $414M by 2035, reflecting strong double-digit growth driven by uptake of novel hormonal therapies.
• Market expansion is supported by:
• Increasing adoption of oral GnRH antagonists and advanced hormonal treatments
• Improved diagnosis and treatment rates
• Despite moderate patient growth, market value is driven by chronic treatment duration and premium-priced therapies.
• Future growth will depend on the development of disease-modifying therapies that provide sustained symptom relief and reduce recurrence rates.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Kissei Pharmaceutical Co., Ltd.
• Hope Medicine (Nanjing) Co., Ltd.
• Organon and Co
• Gesynta Pharma AB
• Nanjing Chia-tai Tianqing Pharmaceutical
• AbbVie
• Sumitomo Pharma Switzerland GmbH
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Jiangsu HengRui Medicine Co., Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)